Event time: 事件时间：
Published: 文章发布：
INSM regulatory decision: FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027Insmed Incorporated（INSM）披露重大监管决定
INSM regulatory decision: FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027.
Insmed Incorporated（INSM）披露重大监管决定。
For information only. Not investment advice.内容仅供参考，不构成投资建议。